SCHEMBL29937121

SCHEMBL29937121

Cc1nc(N)ccc1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.52
NOS2 P35228 2/20 0.52
NOS1 P29475 1/20 0.52
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
BACE1 P56817 4/20 0.43
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42
GABRA4 P48169 1/20 0.42
GABRE P78334 1/20 0.42
GABRA6 Q16445 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14108794 1.00 NOS3 (0.52) NOS3NOS2NOS1KMT2AKDM4E
Formic Acid SCHEMBL31491006 0.89 GABRP (0.43) NOS3NOS2NOS1KMT2AKDM4E
Trifluoroacetic Acid SCHEMBL31491015 0.88 GABRP (0.50) NOS3NOS2NOS1KMT2AKDM4E
Trifluoroacetic Acid SCHEMBL31491055 0.82 CXCR4 (0.46) NOS3NOS2NOS1KMT2AKDM4E
SCHEMBL12019749 0.80 NOS2 (0.54) NOS3NOS2NOS1KMT2AKDM4E
SCHEMBL16256879 0.78 CYP11B1 (0.37) KMT2AKDM4EALDH1A1
SCHEMBL13865687 0.77 RAB9A (0.39) KMT2AALDH1A1BACE1HSP90AA1HSP90AB1
SCHEMBL11272404 0.76 KDM4E (0.46) NOS3NOS2NOS1KMT2AKDM4E
SCHEMBL21139679 0.76 KDM4E (0.42) KMT2AKDM4EALDH1A1HSP90AA1HSP90AB1
SCHEMBL14108777 0.75 NOS3 (0.48) NOS3NOS2NOS1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029167-A Condensed heteroaryl compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2026-05-12 CN disclosed
EP-4716531-A2 HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS Board of Regents, The University of Texas System (US) 2026-04-01 EP disclosed
WO-2025217430-A1 HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-10-16 WO disclosed
CN-119855815-A KRAS mutant protein inhibitor, and preparation method and application thereof 甘李药业股份有限公司 2025-04-18 CN disclosed
WO-2025049274-A2 TETRACYCLIC DERIVATIVES, COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
CN-119365465-A Condensed ring compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-01-24 CN disclosed
CN-119365467-A Aza-tetraepoxy aza compounds and uses thereof 基因泰克公司 2025-01-24 CN disclosed
CN-119317628-A Substituted bridged ring inhibitors and preparation method and application thereof 苏州泽璟生物制药股份有限公司 2025-01-14 CN disclosed
WO-2024243186-A2 HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-11-28 WO disclosed
EP-4322954-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2024-02-21 EP disclosed
WO-2022221739-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT MERCK SHARP & DOHME CORP. (US) 2022-10-20 WO disclosed